Both AP-1 inhibitor and ALK5 inhibitor were preferentially toxic to BCC cells, as they affected cell viability of multiple BCC cell lines25 to a significantly higher degree than noncancerous cell lines (Supplementary Fig. 3i), providing key pre-clinical data for a drug therapeutic window. This evidence concerns the gene FOS and skin basal cell carcinoma.